Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 1,520Virus-based gene therapy researchRNA Interference and Gene DeliveryNeurogenetic and Muscular Disorders Research

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy

Open access
Gao, Guang-Ping, Alvira, Mauricio R., Wang, Lili, Calcedo, Roberto, Johnston, Julie, Wilson, James M.·2002·Proceedings of the National Academy of Sciences

Abstract

Tissues from rhesus monkeys were screened by PCR for the presence of sequences homologous to known adeno-associated virus (AAV) serotypes 1–6. DNA spanning entire rep-cap ORFs from two novel AAVs, called AAV7 and AAV8, were isolated. Sequence comparisons among these and previously described AAVs revealed the greatest divergence in capsid proteins. AAV7 and AAV8 were not neutralized by heterologous antisera raised to the other serotypes. Neutralizing antibodies to AAV7 and AAV8 were rare in human serum and, when present, were low in activity. Vectors formed with capsids from AAV7 and AAV8 were generated by using rep and inverted terminal repeats (ITRs) from AAV2 and were compared with similarly constructed vectors made from capsids of AAV1, AAV2, and AAV5. Murine models of skeletal muscle and liver-directed gene transfer were used to evaluate relative vector performance. AAV7 vectors demonstrated efficiencies of transgene expression in skeletal muscle equivalent to that observed with AAV1, the most efficient known serotype for this application. In liver, transgene expression was 10- to 100-fold higher with AAV8 than observed with other serotypes. This improved efficiency correlated with increased persistence of vector DNA and higher number of transduced hepatocytes. The efficiency of AAV8 vector for liver-directed gene transfer of factor IX was not impacted by preimmunization with the other AAV serotypes. Vectors based on these novel, nonhuman primate AAVs should be considered for human gene therapy because of low reactivity to antibodies directed to human AAVs and because gene transfer efficiency in muscle was similar to that obtained with the best known serotype, whereas, in liver, gene transfer was substantially higher than previously described.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.182412299

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Research works printed but not linked: 2

  1. N Muzyczka, K I Berns Fields Virology, eds D M Knipe, P M Howley (Lippincott Williams & Wilkins, Philadelphia) 2, 2327–2359 (2001).
  2. N R Blacklow, M D Hoggan, W P Rowe J Natl Cancer Inst 40, 319–327 (1968).

Cited by

See all 1,520

Metadata

Authors
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M.
Affiliations
  • Institute for Human Gene Therapy and Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104; and Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104
  • The Wistar Institute (US)
Corresponding author
Wilson, James M.
Venue
Proceedings of the National Academy of Sciences
Published
2002-08-21
Volume
99
Issue
18
Pages
11854-11859
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2047608515
Cited by
1,520
References
36
Citations by year
2026: 27 · 2025: 34 · 2024: 42 · 2023: 46 · 2022: 42 · 2021: 41 · 2020: 50 · 2019: 67 · 2018: 56 · 2017: 56 · 2016: 38 · 2015: 69 · 2014: 65 · 2013: 77 · 2012: 70
FWCI
41.90
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Cystic Fibrosis Foundation
  • GlaxoSmithKline
  • University of Pennsylvania
  • National Institutes of Health (P30 DK)
  • National Heart, Lung, and Blood Institute (P01 HL 59407-03, P01HL059407)
  • National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK 47757-09, P30DK047757)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
Keywords
adeno-associated virus, AAV8, rhesus monkeys, gene therapy vectors, neutralizing antibodies, liver-directed gene transfer, skeletal muscle gene transfer, factor IX, transgene expression, vector persistence, inverted terminal repeats
MeSH terms
Dependovirus, Amino Acid Sequence, Animals, Base Sequence, Capsid, Genetic Vectors, Humans, Macaca mulatta, Mice, Inbred C57BL, Molecular Sequence Data, Genetic Therapy, Sequence Homology, Amino Acid, DNA Primers, Gene Transfer Techniques, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. https://app.cochat.ai/papers/10.1073/pnas.182412299
The paper
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002). Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.182412299

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.